Mr A, age 16 years, is a slow-to-warm-up high-school student from a middle socioeconomic background. He presented for the first time to the clinic with a 2½-year history of school refusal and irritability. On clarification, it was apparent that from a very young age (even before age 5 years) he was excessively concerned about dirt. He would avoid looking at the toilet, even while using it, take an abnormally long time washing his face (his clothes getting wet in the process) and bathing, and would not allow anyone to use his towels. He would also avoid using toilets outside his own house whenever he went on a trip. About 2½ years before presenting to the clinic, he also began to have obsessive images of a dirty bathroom and toilet. Further, he began to fear that he would forget lessons studied and, hence, fail to answer either in class or during examinations. Consequently, he avoided exams and refused to go to school. He also thought that people were talking about him on the road and had checking compulsions yielding to these obsessive doubts, fears that books given to friends might get lost, compulsive reassurance seeking, repeated intrusive ruminations about events during the day, and thoughts that he would be responsible for something bad happening. He was also found to have a history suggesting separation anxiety disorder of childhood, sibling rivalry, and oppositional tendencies, for which psychiatric consultation had not been sought. The family history suggested unspecified mental illness in his maternal grand-aunt and maternal uncle, possible depressive illness in his paternal great-grandmother, and subclinical obsessive-compulsive symptoms in his mother's maternal uncle. Although he had poor insight and was uncooperative for treatment at the time of presentation, he started showing response to sertraline (up to 150 mg daily). Later, he started cooperating with exposure-and response-prevention therapy for his contamination obsessions and with audioexposure therapy for his obsessive fear of forgetting lessons learned. At the end of 4 weeks' inpatient treatment, his obsessions and compulsions showed significant improvement.
This case highlights the fact that OCD may have onset at a very early age and is in keeping with the earlier findings of early onset being associated with male sex and positive family history (3). The long time-lag before this case actually presented to a psychiatrist indicates the need for increased awareness among professionals, especially because the illness arises at a developmentally important period. Recently, Chue and colleagues suggested that new formulations of antipsychotics that are fast-dissolving in the mouth, such as orally disintegrating olanzapine tablets, are welcome. They are seemingly impossible to "cheek" and may improve medication adherence (1). In selected patients, this is true. However, such novel drug formulations are no panacea against noncompliance, which was exemplified by a patient who managed to be noncompliant with fast-dissolving olanzapine tablets (2).
Case Report
Ms A was a 52-year-old woman with chronic schizophrenia and tardive dyskinesia and a long history of noncompliance with antipsychotics, resulting in a cyclical pattern of hospitalizations that alternated with homelessness. Untreated, she was hostile, disorganized, and dishevelled. With antipsychotic treatment, she was pleasant, was able to follow ward routines, and took pride in her appearance, with great concern for potential weight gain. She never regarded herself as ill and always denied the need for medication.
After being involuntarily hospitalized, a 6-month clozapine trial failed, because the patient remained adversarial to taking medications. Despite great staff effort, she decompensated twice in hospital, owing to noncompliance (corroborated by plasma levels).
After she agreed to try out this newly formulated medicine, an olanzapine wafer trial was initiated. Although she was apparently compliant, no clinical improvement occurred after several weeks of olanzapine wafers at a dosage of 20 mg daily. A steady-state olanzapine plasma level was unexpectedly low (8.5 ng/mL). Finally, a nurse observed the following "cheeking" technique: the patient put the Zydis wafer up behind her front teeth near the gum line. It appeared that she kept her mouth dry to allow the wafer to stick in place. In this way, she managed to produce the wafer largely intact, minutes after it was administered. After this experience, she was started on haloperidol decanoate.
Discussion
Patients who appear treatment-resistant could be noncompliant with antipsychotics. This patient had several risk factors for noncompliance: lack of insight into her illness or of medication benefit, a long history of noncompliance, and severe side effects to antipsychotics (3). We nevertheless did not consider noncompliance as a likely possibility, owing to the supervised medication dispensation and a prima facie "foolproof" medication administration method. In hindsight, this was a mistake. Still, patients must be observed closely to ensure that the wafer disintegrates completely and is swallowed, because buccal absorption is negligible.
Thus, this case serves as a reminder that fast-dissolving oral medication is no substitute for parenteral medication.
